



GENOMIC | GENETIC | R&D | DIAGNOSTIC TESTS

Genomic Vision strengthens its leadership team with the appointment of Thierry HUET as R&D Director

Bagneux (France) - Genomic Vision (the "Company" - FR0011799907 – GV), a biotechnology company that develops tools and services dedicated to the analysis and control of modifications in the genome, announced today the appointment of Dr. Thierry HUET as Director of Research and Development.

Thierry has an extensive experience of more than 30 years in both pharmaceutical and biotechnology companies, always managing and leading R&D departments and programs from research to clinic, up to phase 3. Prior to his arrival at Genomic Vision, Thierry successively led R&D of Invectys, Endotis Pharma, Abtech Pharma and Diatos, four biopharmaceutical companies dedicated to the development of innovative "first-in-class" drugs, such as vaccines, immunotherapies, monoclonal antibodies, as well as cell and gene therapies in various diseases, including cancer. Previously, Thierry managed R&D teams and programs for 10 years at Sanofi-Aventis (France and the US) where he successfully led preclinical projects, in particular in gene therapy in the fields of cancer and AIDS. Thierry is co-author of about 20 peer-reviewed scientific publications and co-inventor of 6 patent families in various technological and therapeutic areas.

Thierry holds a Ph.D. in molecular virology from the University of Paris and conducted his doctoral work at the Pasteur Institute in Paris. He also holds an Executive Certificate in General Management and Strategy from ESCP, a renowned international Business School (Paris).

"Joining a company such as Genomic Vision, with its high potential technology in the field of structural and functional genomic analysis, covering unmet needs in terms of diagnostic and prognostic biomarkers, is particularly exciting and motivating. I am delighted to contribute, with my 30 years of passion and experience, to the ramp-up of the R&D of the company" **said Thierry HUET, Director of R&D at Genomic Vision.**

Dominique REMY-RENOU, CEO of Genomic Vision, commented: *"We are very pleased to welcome Thierry HUET as Director of Research and Development to the Genomic Vision team. This appointment completes the renewal of our management team. Thierry's experience and expertise will be instrumental to expand even further our molecular combing-based solutions and to meet the demands of our target markets."*

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company developing products and services dedicated to the structural and functional analysis of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Genomic Vision, based near Paris in Bagneux, is a public listed company listed in compartment C of Euronext's regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit www.genomicvision.com

CONTACTS

Genomic Vision

Dominique Remy-Renou

CEO

Tel.: +33 1 49 08 07 51

investisseurs@genomicvision.com

Ulysse Communication

Press Relations

Bruno Arabian

Tel.: +33 1 42 68 29 70

[barabian@ulyссе-](mailto:barabian@ulyссе-communication.com)

communication.com

NewCap

Investor Relations

& Strategic Communications

Tel.: +33 1 44 71 94 94

gv@newcap.eu



Member of the CAC[®] Mid & Small and CAC[®] All-Tradable indexes

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the "Risk Factors" section of the universal registration document filed with the AMF on February 9, 2021 under reference number R.21-002, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.